STOCK TITAN

[Form 4] Corvus Pharmaceuticals, Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Corvus Pharmaceuticals, Inc. (CRVS) – Form 4 insider activity dated 06/27/2025

Director and 10% owner Peter A. Thompson, acting through OrbiMed Private Investments V, LP (OPI V), exercised 1,397,684 common stock warrants at $3.50 just before their 06/30/2025 expiry. The warrants were settled on a cashless basis: the issuer withheld 1,176,332 shares (coded “S”) to fund the exercise, and issued 221,352 new shares to OPI V (coded “X”). Following the transactions, Thompson/OPI V’s indirect beneficial ownership stands at 7,165,006 shares.

The filing shows a small net increase in insider ownership and a modest share-count expansion for the company. No open-market sales were reported; the disposition reflects internal share withholding rather than a public sale.

Corvus Pharmaceuticals, Inc. (CRVS) – Attività insider Form 4 datata 27/06/2025

Il direttore e azionista con il 10% Peter A. Thompson, tramite OrbiMed Private Investments V, LP (OPI V), ha esercitato 1.397.684 warrant su azioni ordinarie a $3,50 poco prima della loro scadenza del 30/06/2025. I warrant sono stati regolati su base cashless: l'emittente ha trattenuto 1.176.332 azioni (codice “S”) per finanziare l'esercizio, e ha emesso 221.352 nuove azioni a favore di OPI V (codice “X”). Dopo queste operazioni, la posizione di proprietà indiretta di Thompson/OPI V è di 7.165.006 azioni.

La comunicazione evidenzia un piccolo aumento netto nella proprietà insider e una modesta espansione del numero di azioni della società. Non sono state segnalate vendite sul mercato aperto; la disposizione riflette una trattenuta interna di azioni e non una vendita pubblica.

Corvus Pharmaceuticals, Inc. (CRVS) – Actividad de insiders Formulario 4 fechada 27/06/2025

El director y propietario del 10% Peter A. Thompson, actuando a través de OrbiMed Private Investments V, LP (OPI V), ejerció 1.397.684 warrants de acciones comunes a $3.50 justo antes de su vencimiento el 30/06/2025. Los warrants se liquidaron en base cashless: el emisor retuvo 1.176.332 acciones (código “S”) para financiar el ejercicio y emitió 221.352 acciones nuevas a OPI V (código “X”). Tras las transacciones, la propiedad indirecta beneficiaria de Thompson/OPI V es de 7.165.006 acciones.

La presentación muestra un pequeño aumento neto en la propiedad insider y una modesta expansión en el número de acciones de la compañía. No se reportaron ventas en el mercado abierto; la disposición refleja una retención interna de acciones en lugar de una venta pública.

Corvus Pharmaceuticals, Inc. (CRVS) – 2025년 6월 27일자 Form 4 내부자 거래 내역

이사이자 10% 지분 보유자인 Peter A. Thompson는 OrbiMed Private Investments V, LP (OPI V)를 통해 만료일인 2025년 6월 30일 직전에 주당 $3.50에 1,397,684주 보통주 워런트를 행사했습니다. 워런트는 현금 없이(cashless) 정산되었으며, 발행사는 행사 자금 조달을 위해 1,176,332주(코드 “S”)를 원천징수하고, 221,352주의 신주를 OPI V에 발행했습니다(코드 “X”). 거래 후 Thompson/OPI V의 간접적 실소유 주식 수는 7,165,006주입니다.

이번 신고는 내부자 지분의 소폭 순증과 회사의 주식 수의 다소 확장을 보여줍니다. 공개 시장에서의 매도는 보고되지 않았으며, 이번 처분은 공개 매도가 아닌 내부 주식 원천징수에 해당합니다.

Corvus Pharmaceuticals, Inc. (CRVS) – Activité des initiés Formulaire 4 datée du 27/06/2025

Le directeur et détenteur de 10% Peter A. Thompson, agissant par l'intermédiaire d'OrbiMed Private Investments V, LP (OPI V), a exercé 1 397 684 bons de souscription d'actions ordinaires à 3,50 $ juste avant leur expiration le 30/06/2025. Les bons ont été réglés sur une base sans numéraire : l'émetteur a retenu 1 176 332 actions (code « S ») pour financer l'exercice, et a émis 221 352 nouvelles actions à OPI V (code « X »). Suite à ces transactions, la détention bénéficiaire indirecte de Thompson/OPI V s'élève à 7 165 006 actions.

Le dépôt indique une légère augmentation nette de la détention des initiés et une modeste augmentation du nombre d'actions de la société. Aucune vente sur le marché ouvert n'a été signalée ; la disposition reflète une retenue interne d'actions plutôt qu'une vente publique.

Corvus Pharmaceuticals, Inc. (CRVS) – Form 4 Insider-Aktivität vom 27.06.2025

Direktor und 10%-Eigentümer Peter A. Thompson hat über OrbiMed Private Investments V, LP (OPI V) 1.397.684 Stammaktien-Warrants zu je 3,50 $ kurz vor deren Ablauf am 30.06.2025 ausgeübt. Die Warrants wurden auf bargeldloser Basis abgewickelt: Der Emittent behielt 1.176.332 Aktien (Code „S“) ein, um die Ausübung zu finanzieren, und gab 221.352 neue Aktien an OPI V aus (Code „X“). Nach den Transaktionen hält Thompson/OPI V indirekt 7.165.006 Aktien.

Die Meldung zeigt einen kleinen Nettoanstieg des Insiderbesitzes und eine moderate Erhöhung der Aktienanzahl des Unternehmens. Es wurden keine Verkäufe am offenen Markt gemeldet; die Transaktion spiegelt eine interne Aktienrückhaltung und keinen öffentlichen Verkauf wider.

Positive
  • Insider confidence: Director/10% owner increased net holdings by 221,352 shares through warrant exercise.
  • No open-market selling: Shares withheld to cover exercise price, avoiding additional market supply.
Negative
  • Minor dilution: Issuance of 221,352 new shares slightly increases outstanding share count.

Insights

TL;DR — Insider exercises expiring warrants, nets 221k new shares; marginal dilution, signals continued commitment.

The cashless exercise converts near-term expiring warrants without cash outlay, avoiding market overhang. While 1.18 million shares were technically “sold,” they were withheld by the issuer, so no fresh supply hit the market. The net issuance of 221,352 shares (≈0.3% of a 70 m share base if similar-sized peers are used) is immaterial dilution. Insider now holds 7.17 m shares, reinforcing strategic alignment. Overall impact is neutral-to-slightly positive, indicating confidence but lacking broader financial implications.

TL;DR — Routine Section 16 filing; ownership clarity maintained, no governance red flags detected.

The disclosure satisfies Section 16 requirements and clarifies indirect ownership through OrbiMed entities. All disclaimers regarding beneficial ownership are standard. The conversion ahead of warrant expiry demonstrates orderly insider behavior, limiting potential conflicts. No evidence of aggressive selling or rule-10b5-1 usage is noted. Consequently, governance risk remains unchanged.

Corvus Pharmaceuticals, Inc. (CRVS) – Attività insider Form 4 datata 27/06/2025

Il direttore e azionista con il 10% Peter A. Thompson, tramite OrbiMed Private Investments V, LP (OPI V), ha esercitato 1.397.684 warrant su azioni ordinarie a $3,50 poco prima della loro scadenza del 30/06/2025. I warrant sono stati regolati su base cashless: l'emittente ha trattenuto 1.176.332 azioni (codice “S”) per finanziare l'esercizio, e ha emesso 221.352 nuove azioni a favore di OPI V (codice “X”). Dopo queste operazioni, la posizione di proprietà indiretta di Thompson/OPI V è di 7.165.006 azioni.

La comunicazione evidenzia un piccolo aumento netto nella proprietà insider e una modesta espansione del numero di azioni della società. Non sono state segnalate vendite sul mercato aperto; la disposizione riflette una trattenuta interna di azioni e non una vendita pubblica.

Corvus Pharmaceuticals, Inc. (CRVS) – Actividad de insiders Formulario 4 fechada 27/06/2025

El director y propietario del 10% Peter A. Thompson, actuando a través de OrbiMed Private Investments V, LP (OPI V), ejerció 1.397.684 warrants de acciones comunes a $3.50 justo antes de su vencimiento el 30/06/2025. Los warrants se liquidaron en base cashless: el emisor retuvo 1.176.332 acciones (código “S”) para financiar el ejercicio y emitió 221.352 acciones nuevas a OPI V (código “X”). Tras las transacciones, la propiedad indirecta beneficiaria de Thompson/OPI V es de 7.165.006 acciones.

La presentación muestra un pequeño aumento neto en la propiedad insider y una modesta expansión en el número de acciones de la compañía. No se reportaron ventas en el mercado abierto; la disposición refleja una retención interna de acciones en lugar de una venta pública.

Corvus Pharmaceuticals, Inc. (CRVS) – 2025년 6월 27일자 Form 4 내부자 거래 내역

이사이자 10% 지분 보유자인 Peter A. Thompson는 OrbiMed Private Investments V, LP (OPI V)를 통해 만료일인 2025년 6월 30일 직전에 주당 $3.50에 1,397,684주 보통주 워런트를 행사했습니다. 워런트는 현금 없이(cashless) 정산되었으며, 발행사는 행사 자금 조달을 위해 1,176,332주(코드 “S”)를 원천징수하고, 221,352주의 신주를 OPI V에 발행했습니다(코드 “X”). 거래 후 Thompson/OPI V의 간접적 실소유 주식 수는 7,165,006주입니다.

이번 신고는 내부자 지분의 소폭 순증과 회사의 주식 수의 다소 확장을 보여줍니다. 공개 시장에서의 매도는 보고되지 않았으며, 이번 처분은 공개 매도가 아닌 내부 주식 원천징수에 해당합니다.

Corvus Pharmaceuticals, Inc. (CRVS) – Activité des initiés Formulaire 4 datée du 27/06/2025

Le directeur et détenteur de 10% Peter A. Thompson, agissant par l'intermédiaire d'OrbiMed Private Investments V, LP (OPI V), a exercé 1 397 684 bons de souscription d'actions ordinaires à 3,50 $ juste avant leur expiration le 30/06/2025. Les bons ont été réglés sur une base sans numéraire : l'émetteur a retenu 1 176 332 actions (code « S ») pour financer l'exercice, et a émis 221 352 nouvelles actions à OPI V (code « X »). Suite à ces transactions, la détention bénéficiaire indirecte de Thompson/OPI V s'élève à 7 165 006 actions.

Le dépôt indique une légère augmentation nette de la détention des initiés et une modeste augmentation du nombre d'actions de la société. Aucune vente sur le marché ouvert n'a été signalée ; la disposition reflète une retenue interne d'actions plutôt qu'une vente publique.

Corvus Pharmaceuticals, Inc. (CRVS) – Form 4 Insider-Aktivität vom 27.06.2025

Direktor und 10%-Eigentümer Peter A. Thompson hat über OrbiMed Private Investments V, LP (OPI V) 1.397.684 Stammaktien-Warrants zu je 3,50 $ kurz vor deren Ablauf am 30.06.2025 ausgeübt. Die Warrants wurden auf bargeldloser Basis abgewickelt: Der Emittent behielt 1.176.332 Aktien (Code „S“) ein, um die Ausübung zu finanzieren, und gab 221.352 neue Aktien an OPI V aus (Code „X“). Nach den Transaktionen hält Thompson/OPI V indirekt 7.165.006 Aktien.

Die Meldung zeigt einen kleinen Nettoanstieg des Insiderbesitzes und eine moderate Erhöhung der Aktienanzahl des Unternehmens. Es wurden keine Verkäufe am offenen Markt gemeldet; die Transaktion spiegelt eine interne Aktienrückhaltung und keinen öffentlichen Verkauf wider.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Thompson Peter A.

(Last) (First) (Middle)
C/O CORVUS PHARMACEUTICALS, INC.
901 GATEWAY BOULEVARD, THIRD FLOOR

(Street)
SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Corvus Pharmaceuticals, Inc. [ CRVS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/27/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/27/2025 X 1,397,684 A $3.5 8,341,338 I See Footnotes(2)(3)
Common Stock 06/27/2025 S(1) 1,176,332 D $4.1586 7,165,006 I See Footnotes(2)(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Common Warrants (right to buy) $3.5 06/27/2025 X 1,397,684 04/29/2025 06/30/2025 Common Stock 1,397,684 $0 0 I See Footnotes(2)(3)
Explanation of Responses:
1. On June 27, 2025, OrbiMed Private Investments V, LP ("OPI V") exercised common warrants ("Warrants") to purchase 1,397,684 shares of the Issuer's Common Stock for $3.50 per share. OPI V paid the exercise price on a cashless basis, resulting in the Issuer withholding 1,176,332 of the Warrant shares to pay the exercise price and issuing to OPI V the remaining 221,352 shares.
2. These securities are held of record by OPI V. OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V. The Reporting Person is a member of Advisors.
3. Each of the Reporting Person, OrbiMed Advisors, and GP V disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
/s/ Peter A. Thompson 07/01/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many CRVS shares did the insider acquire on 06/27/2025?

OrbiMed Private Investments V received 221,352 new shares after a cashless warrant exercise.

What was the exercise price of the CRVS warrants?

The warrants were exercised at $3.50 per share.

How many CRVS shares does the insider own after the transaction?

Indirect beneficial ownership stands at 7,165,006 common shares.

Were any CRVS shares sold on the open market?

No. The 1,176,332 shares marked as disposition were withheld by the issuer to fund the cashless exercise.

When did the exercised warrants expire?

The warrants had an expiration date of 06/30/2025.
Corvus Pharmaceu

NASDAQ:CRVS

CRVS Rankings

CRVS Latest News

CRVS Latest SEC Filings

CRVS Stock Data

297.66M
62.14M
3.44%
58.77%
8.32%
Biotechnology
Pharmaceutical Preparations
Link
United States
BURLINGAME